logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9073853 B1

PDFFull Text
Date of Patent:
Jul. 07, 2015

Filed:

Jun. 03, 2014

Cycloalkane carboxylic acid derivatives as cxcr3 receptor antagonists

Applicant:

Sanofi, Paris, FR;

Inventors:

Imre Bata, Budapest, HU;

Peter Buzder-Lantos, Budapest, HU;

Attila Vasas, Dunakeszi, HU;

Veronika Bartane Bodor, Budapest, HU;

Gyorgy Ferenczy, Budapest, HU;

Zsuzsanna Tomoskozi, Budapest, HU;

Gabor Szeleczky, Budapest, HU;

Sandor Batori, Budapest, HU;

Martin Smrcina, Tucson, AZ (US);

Marcel Patek, Tucson, AZ (US);

Aleksandra Weichsel, Tucson, AZ (US);

David Squire Thorpe, Tucson, AZ (US);

Assignee:

SANOFI, Paris, FR;

Attorney:

Ronald G. Ort

Primary Examiner:

Matthew Coughlin

Int. Cl.
CPC ...
C07D 207/408 (2006.01); C07D 209/52 (2006.01); C07D 277/34 (2006.01); C07D 239/54 (2006.01); C07D 417/12 (2006.01); C07D 209/48 (2006.01); C07D 207/40 (2006.01); C07D 405/12 (2006.01); C07D 251/20 (2006.01); C07D 263/44 (2006.01); C07D 221/20 (2006.01); C07D 413/12 (2006.01); C07D 233/74 (2006.01); C07D 211/88 (2006.01); A61K 31/53 (2006.01); A61K 31/506 (2006.01); A61K 31/513 (2006.01); A61K 31/45 (2006.01); A61K 31/438 (2006.01); A61K 31/4015 (2006.01); A61K 31/4035 (2006.01); A61K 31/4166 (2006.01); A61K 31/403 (2006.01); A61K 31/421 (2006.01); A61K 31/427 (2006.01); A61K 31/426 (2006.01); C07D 209/94 (2006.01);
U.S. Cl.
CPC ...
C07D 207/408 (2013.01); A61K 31/53 (2013.01); A61K 31/427 (2013.01); A61K 31/506 (2013.01); A61K 31/45 (2013.01); A61K 31/513 (2013.01); A61K 31/438 (2013.01); A61K 31/403 (2013.01); A61K 31/4166 (2013.01); A61K 31/4015 (2013.01); A61K 31/4035 (2013.01); A61K 31/421 (2013.01); A61K 31/426 (2013.01); C07D 211/88 (2013.01); C07D 221/20 (2013.01); C07D 233/74 (2013.01); C07D 405/12 (2013.01); C07D 239/54 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C07D 251/20 (2013.01); C07D 263/44 (2013.01); C07D 207/40 (2013.01); C07D 277/34 (2013.01); C07D 209/48 (2013.01); C07D 209/94 (2013.01); C07D 209/52 (2013.01);
Abstract

The present invention relates to compounds of formula 1 that are useful for the preventive or therapeutic treatment of diseases caused by abnormal activation of CXCR3 chemokines. The invention relates furthermore to a process for the preparation of said compounds, to pharmaceutical compositions containing said compounds and to novel intermediates used in the preparation of said compounds.

Find Patent Forward Citations

Loading…